Wolfgang Miesbach: Immune-Engineered AAV Capsids Displaying IL-10 Enhance Gene Therapy Safety and Efficacy
Wolfgang Miesbach, Head of Hemostasis/Hemophilia Center at Medical Clinic 2 at University Hospital Frankfurt, shared a post on LinkedIn:
“Don’t suppress the immune system.
Teach it.
ESGCT26, Carmen Unzu on leveraging immune recognition for safer and more potent AAV gene therapy.
IL-10 is one of the body’s own brakes on inflammation: a cytokine that dampens pro-inflammatory signalling, limits antigen presentation and T-cell activation, and favours regulatory T cells.
Tolerance rather than suppression.
Anti-AAV immunity costs us at every stage.
Neutralising antibodies exclude patients before dosing, immune recognition erodes efficacy and safety during treatment, and the antibody response afterwards closes the door on re-dosing.
Our current answer is pharmacological immunosuppression: broad, prolonged, with a side-effect profile of its own.
The concept: build the immunomodulation into the vector itself rather than give it as a separate drug.
Two routes, compared in mice: an IL-10-derived peptide displayed genetically on the AAV8 capsid, acting transiently from the moment of dosing; or AAV-mediated IL-10 expression from the genome, sustained and transgene-dependent.
Her conclusions: incorporating an immunomodulatory agent into the capsid was sufficient to induce a durable immune change, and transient peptide display enhanced transgene expression while selectively reducing AAV immunogenicity after systemic administration.”
Stay updated with Hemostasis Today.
-
Nov 7, 2026, 17:03Nicole Dobkin: Survey Reveals Major Disconnect Between Access to Apheresis and Patient Utilization in Sickle Cell Care
-
Nov 7, 2026, 16:58Muhammad Essa: Comparing Indobufen and Aspirin in Acute Ischemic Stroke
-
Nov 7, 2026, 16:42Inderpaul Birdi: Warfarin or Newer Blood Thinners?
-
Nov 7, 2026, 16:31Arwa Z. Al-Riyami: EMR Transfusion Medicine Featured in October 2026 Issue of ISBT Transfusion Today
-
Nov 7, 2026, 16:31Rafael Gomes: Is Dual Antiplatelet Therapy Still Necessary After LAAO?
-
Nov 7, 2026, 16:15Mazyar Shadman: Novel BTK Inhibitors and DOACs A Multicenter Study of Bleeding Risk
-
Nov 7, 2026, 15:54Hassan Raza: Beyond the 100 Minus Age Rule in Bone Marrow Cellularity
-
Nov 7, 2026, 15:42Andrew ZapfelÖ‰ Advancing Sickle Cell Disease Care Through Training, Advocacy and Collaboration
-
Nov 7, 2026, 15:34Salih Ehsan: Iron Deficiency Beyond Conventional Ferritin Cutoffs